Roadmap for use of KIs in CLL. The decision to continue or switch KI therapy in CLL is based on the severity and timing of previous toxicity and quality of response. In patients with early toxicity or responding patients who have delayed non–life-threatening AEs, consideration can be given to dose interruption or reduction. In patients who progress or develop severe or chronic toxicity, alternate class or alternate target inhibitor should be considered.